Suppr超能文献

脊髓损伤临床试验参与的促进因素与障碍:脊髓损伤患者的多国视角

Facilitators and Barriers to Spinal Cord Injury Clinical Trial Participation: Multi-National Perspective of People Living with Spinal Cord Injury.

作者信息

Anderson Kim D, Cowan Rachel E, Horsewell Jane

机构信息

1 Department of Neurological Surgery, Miami Project to Cure Paralysis, University of Miami Leonard M. Miller School of Medicine , Miami, Florida.

2 The European Spinal Cord Injury Federation, Nottwil, Switzerland .

出版信息

J Neurotrauma. 2016 Mar 1;33(5):493-9. doi: 10.1089/neu.2015.4064. Epub 2015 Dec 2.

Abstract

These are exciting times for the translation of promising interventions for spinal cord injury (SCI) into testing with clinical trials. These interventions include acute surgical decompression, neuroprotection, neural repair, cell replacement, activity-based rehabilitation, and medical devices, including devices requiring surgical implantation. By nature, clinical trials can have strict inclusion and exclusion criteria, which narrow down the pool of potential participants. Meeting enrollment numbers for properly powered trials is a daunting task. Therefore, it is important that trials are designed in a manner that facilitates participation. The purpose of this research study was to learn more about the factors that encourage or interfere with the decision to participate in clinical trials from the perspective of people living with SCI. A multi-national survey was conducted, primarily online, in which 802 participants with SCI ranked 32 factors as facilitators or barriers, using a Likert-type scale. There were 13 universal facilitators, five universal barriers, and three universally neutral factors. The number one facilitator was possible improvement in functionality and the number one barrier was possible decline in functionality--as may be expected. However, many unexpected facilitators and barriers were identified. There also were certain factors that were strong barriers or facilitators to certain sub-groups of people living with SCI. All of these factors should be taken into careful consideration when designing clinical trials so as to promote enrollment and enable adherence to different protocols.

摘要

对于将有前景的脊髓损伤(SCI)干预措施转化为临床试验测试而言,现在是激动人心的时刻。这些干预措施包括急性手术减压、神经保护、神经修复、细胞替代、基于活动的康复以及医疗设备,包括需要手术植入的设备。从本质上讲,临床试验可能有严格的纳入和排除标准,这会缩小潜在参与者的范围。为规模适当的试验招募到足够数量的参与者是一项艰巨的任务。因此,以促进参与的方式设计试验非常重要。本研究的目的是从脊髓损伤患者的角度,更多地了解鼓励或干扰参与临床试验决策的因素。开展了一项主要通过在线方式进行的多国调查,802名脊髓损伤参与者使用李克特量表将32个因素列为促进因素或障碍因素。有13个普遍的促进因素、5个普遍的障碍因素和3个普遍中立的因素。排名第一的促进因素是功能可能改善,排名第一的障碍因素是功能可能下降——这在意料之中。然而,也发现了许多意想不到的促进因素和障碍因素。对于某些脊髓损伤患者亚组,也存在某些因素是强大的障碍或促进因素。在设计临床试验时,所有这些因素都应仔细考虑,以促进招募并使患者遵守不同的方案。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验